GBD-9 - ≥99% , CAS No.2864408-92-2

CAS: 2864408-92-2 Cat. No.: G1449935 Summenformel: C₄₄H₄₇N₉O₆ Molekulargewicht: 797.90

GRADE & PURITY ≥99%

Storage

Protected from light,Store at -20°C,Desiccated

Shipped In

Ice chest + Ice pads

Übersicht

GBD-9 is a double-mechanism degrader that efficiently degrades BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 acts both as a PROTAC molecule to induce the degradation of BTK and as a molecular glue to degrade GSPT1. GBD-9 effectively inhibits cancer cell growth.

Specifications

Spezifikationen & Reinheit

≥99%

Storage

Protected from light,Store at -20°C,Desiccated

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Aktionsart

INHIBITOR

Reinheit

≥99%

Namen und Kennungen

Molekulargewicht

797.90

Application Protocols

No vendor-tested biological application protocols are provided for this product. The following general procedures are commonly used for small-molecule screening compounds.

• Preparing a DMSO stock

  • Allow vial to equilibrate to room temperature in the dark and dry environment.
  • Weigh required amount rapidly (desiccated handling) and dissolve in anhydrous DMSO to 10–50 mM.
  • Vortex and, if necessary, sonicate briefly. Filter through 0.22 μm PTFE if solution is hazy.
  • Aliquot into amber, low-bind tubes; store at −20 °C.

• Plate preparation (HTS-compatible)

  • Thaw a single-use aliquot on ice and keep protected from light.
  • Dispense by acoustic or pin-tool transfer to minimize DMSO carryover; aim for ≤0.5–1% final DMSO.
  • Include vehicle controls (matching DMSO %) and, if available, positive/negative assay controls.

• Documentation

  • Record SKU (G1449935), CAS (2864408-92-2), lot number, stock concentration, and dispensing log in ELN/LIMS.

These steps are general guidance only. Adapt to your assay requirements and consult the SDS for safety.

Biological Roles

No biological role, target, or pathway information is provided for GBD-9 in the Product Data. Accordingly, no mechanistic or functional assertions are made for this material.

General research context (non-clinical)

• As an uncharacterized small molecule in a compound library, GBD-9 may be used as a test article to interrogate biochemical pathways or cellular phenotypes in discovery assays.
• Any putative biological roles should be established experimentally by the end user through validated assays and orthogonal follow-up. Avoid extrapolating function from code names alone.

Good practices

• Implement appropriate counterscreens to deconvolute nonspecific effects (e.g., aggregation, fluorescence interference, redox activity) before inferring target-related biology.
• Document exact solvent composition and dosing regimen to distinguish vehicle effects from compound-specific phenotypes.

Note: For research use only. No clinical or diagnostic use is intended or implied.

Buffer Applications

This item is not a buffer component. No buffering capacity, pKa, or recommended buffer systems are provided in the Product Data.

Practical guidance (if used in aqueous assays)

• Prepare a concentrated DMSO stock and dilute into the desired assay buffer (e.g., PBS, HEPES, Tris) with rigorous mixing to prevent precipitation.
• Keep final organic cosolvent low (commonly ≤0.5–1% v/v) to maintain buffer performance and biological assay integrity.
• If the compound’s ionization state (pKa) becomes available, select buffer pH to control solubility/charge state as needed.

For buffer recipes and pH ranges, use standard references for PBS, HEPES (pH 6.8–8.2), MOPS (pH 6.5–7.9), and Tris (pH 7–9).

Green Alternatives

Item-specific environmental metrics are not available. However, solvent and process choices around this small molecule can be optimized using greener chemistry principles.

• Prefer greener solvents for dilution and cleanup where compatible (e.g., ethanol, isopropanol, ethyl acetate) over higher-toxicity options (DMF, NMP). Recognize that DMSO remains a practical standard for stock solutions due to unmatched solubilizing power.
• Minimize solvent volumes via high-concentration mother stocks and acoustic or pin-tool dispensing for screening plates.
• Use amber, reusable glassware and minimize single-use plastics during aliquoting when feasible.

Illustrative trade-offs (general)

• DMSO vs 2-propanol: DMSO offers broader solubility and better solution stability; 2-propanol is greener but may not solubilize lipophilic scaffolds sufficiently.
• DMF/NMP replacements: Consider Cyrene or propylene carbonate for some workflows; verify assay compatibility and solubility.

Small comparison (general)

• Parameter | DMSO | Ethanol
• Greenness (qualitative) | Moderate | Higher
• Solubilizing power | Very high | Moderate
• Assay tolerance | High (≤1% v/v) | Variable (≤1–2% v/v)

Adopt waste minimization: consolidate small waste streams and use microscale analytics (LC–MS) to cut consumption.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation use is provided for this product. It is supplied strictly for research use only.

General considerations (non-clinical R&D)

• If used in pre-formulation research, assess solubility and stability across common vehicles (e.g., DMSO, PEG400, Captisol, aqueous buffers) purely for laboratory studies.
• Evaluate compound liabilities early (chemical stability, light sensitivity, hygroscopicity) as the Product Data specify protection from light and desiccated storage.
• Do not use in humans or for diagnostic purposes. No therapeutic claims are made or implied.

Physical Properties

Item-specific physico-chemical specifications are not provided in the Product Data.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable/unknown for solids; Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• LogP, pKa: Not specified for this item; refer to CoA/Spec Sheet.

General laboratory considerations (literature/practice-based)

• Library compounds are commonly provided as dry films or powders designed for dissolution in high-boiling polar aprotic solvents (e.g., DMSO) at 10–50 mM for screening plate preparation.
• If insolubility in DMSO is encountered, trial cosolvents include DMF, NMP, ethanol, or aqueous buffers with ≤1–5% DMSO, depending on assay tolerance.
• For hygroscopic or light-sensitive analytes, rapid handling under low-humidity conditions and amber vials are advised (this item is specified to be protected from light and stored desiccated).

Analytical characterization (recommended practice)

• Confirm identity/purity prior to critical studies by LC–MS and 1H NMR; record retention time and mass for future QC.
• Assess solution stability at intended storage temperature (e.g., 4 °C vs −20 °C) by periodic LC–MS.

Quality and Grades

Grade/purity and analytical release criteria are not specified in the Product Data.

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• Typical documentation: CoA may include purity (e.g., HPLC/LC–MS), water content, residual solvents, and structural confirmation (NMR or MS). Request as needed for regulated workflows.

Interpretation of common grades (general guidance)

• Screening/compound library grade: Intended for discovery assays and SAR; usually accompanied by chromatographic purity (often ≥95% by HPLC) but may not include detailed elemental/metals analysis.
• Analytical reagent (AR) or HPLC grade (if applicable): Indicates tighter control of impurities/UV background—no such designation is provided for this item.

Practical quality control suggestions

• Verify purity and identity upon receipt by LC–MS (single major peak at target m/z) and by 1H NMR if material quantity permits.
• For plate-based screening, prepare a mother DMSO stock and record exact concentration by weight/volume; if high precision is required, titrate by quantitative NMR (qNMR) against an internal standard.

Stabilizers/inhibitors

• Stabilizer content: Not specified for this item; refer to CoA/Spec Sheet.
• If stability is a concern, consider aliquoting into single-use vials to minimize freeze–thaw and headspace oxygen exposure.

Reaction and Applications

This product is supplied as a small-molecule library member for discovery workflows rather than as a general-purpose reagent. No specific reactivity or application notes are provided in the Product Data.

Research applications (general, non-clinical)

• Biochemical and cell-based screening as an uncharacterized test article to probe phenotypes, target engagement, or assay robustness.
• Hit-finding and SAR: Use as a seed structure for initial structure–activity assessments when combined with analogs or matched molecular pairs.
• Probe development workflows: If activity is observed, derivatize for affinity reagents (e.g., photo-crosslinkers, biotin tags) depending on the structure (obtain from CoA).

Practical tips

• Prepare fresh DMSO mother stocks (e.g., 10–50 mM), filter if necessary (0.22 μm PTFE) to remove particulates.
• Track freeze–thaw history; aliquot to single-use vials to preserve integrity.
• Record exact mass, lot number, and preparation details in ELN/LIMS to support reproducibility.

Analytical follow-up

• If activity is observed, confirm identity/purity of the working solution by LC–MS and check for degradation products.
• Consider orthogonal assays to rule out aggregation or redox cycling artifacts (e.g., detergent supplementation, counter-screens).

Reaction Conditions

No reaction conditions are applicable, as this product is provided as a screening-library small molecule rather than a reagent for a defined transformation, and no functional group information is supplied.

General lab handling conditions (practical guidance)

• Stock preparation: Dissolve in DMSO to 10–50 mM, aided by gentle warming (≤40 °C) or sonication as needed. Filter (0.22 μm PTFE) if particulates persist.
• Assay dosing: Dilute stocks into assay media to the desired final concentration while limiting DMSO to ≤0.5–1% v/v where possible.
• Stability checks: Verify stability of working solutions over the intended assay window by LC–MS.

If synthetic use is later intended, consult the CoA for structure and employ standard condition screens (solvent, base/acid, temperature) tailored to the functional groups present.

Safety and Handling

Safety data specific to GBD-9 are not provided in the Product Data. Treat as a research-use-only small molecule of unknown hazard profile.

• GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to SDS.
• Primary hazards: Unknown; handle as potentially harmful if swallowed, inhaled, or in contact with skin. Avoid aerosolization and skin/eye exposure.

Handling practices

• PPE: Wear lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Work in a fume hood when weighing, dissolving, or aliquoting.
• Incompatibilities: Unknown; as a precaution, keep away from strong oxidizers/reductants and acids/bases until compatibility is known.
• Light/moisture sensitivity: Product Data specifies protection from light and desiccated storage; minimize ambient exposure and use amber vials.

First aid (overview; defer to SDS)

• Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical advice.
• Inhalation: Move to fresh air; seek medical attention if symptoms occur.
• Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.

Spill and waste

• Small spills: Absorb with inert material, collect, and dispose per institutional hazardous waste procedures.
• Waste: Dispose as organic laboratory waste; do not discharge to drains.

Always consult and retain the product SDS for authoritative safety information prior to use.

Solvent Selection

Item-specific solubility data are not provided. The following approach reflects common best practices for small-molecule library compounds.

• Primary solvent: DMSO is typically first-line due to broad solubilizing power and assay compatibility at ≤0.5–1% v/v.
• Secondary solvents: DMF or NMP for recalcitrant compounds (ensure assay compatibility). Ethanol or isopropanol can assist as co-solvents.
• Aqueous work: Prepare a concentrated DMSO stock (e.g., 10–50 mM) and dilute into buffer with vigorous mixing; keep final DMSO low to avoid assay interference.

Pragmatic decision flow (general)

• Start with DMSO at 10 mg/mL; if insoluble, warm gently (≤40 °C), sonicate, or add a small fraction of DMF.
• For acid/base functional compounds (if known from CoA), adjust pH of aqueous media to favor ionization for solubilization.

Comparison notes (general)

• DMSO vs DMF: DMSO offers better biological assay tolerance; DMF may enhance solubility but is less preferred in live-cell assays.
• DMSO vs ethanol: Ethanol is more volatile and sometimes less effective for highly lipophilic scaffolds but can reduce DMSO-related assay artifacts.

Always perform a small-scale solubility screen and verify clarity by visual inspection and rapid centrifugation/filtration prior to assay use.

Storage and Reconstitution

Item-specific storage instructions are provided in the Product Data.

• Storage conditions (item-specific)

  • Protected from light (store in amber containers or wrap in foil).
  • Store at −20 °C.
  • Desiccated storage recommended.
  • Shipped in ice chest with ice pads.

• Reconstitution (general guidance for library compounds)

  • Equilibrate closed vial to room temperature before opening to avoid condensation.
  • Dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM); adjust concentration to assay needs.
  • Mix thoroughly; if insoluble, apply gentle warming (≤40 °C) or brief sonication. Avoid prolonged heating or exposure to light.

• Aliquoting and stability

  • Prepare single-use aliquots in amber tubes to minimize freeze–thaw cycles and photodegradation.
  • Record preparation date; for working solutions, confirm stability by LC–MS at intervals appropriate to your study.

• Shelf life

  • Not specified for this item; refer to CoA/Spec Sheet.

Follow institutional best practices and consult the SDS for detailed safety during storage and handling. For research use only.

Structure and Identity

A screening-library small molecule supplied under the code name GBD-9. Structural identifiers for this specific lot are not included in the Product Data.

• Chemical name: Not specified for this item; refer to CoA/Spec Sheet.
• Synonyms: Not specified for this item; refer to CoA/Spec Sheet.
• CAS: 2864408-92-2 (item-specific)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural description

• 2D features, ring systems, heteroatoms, and stereochemistry: Not specified for this item; refer to CoA/Spec Sheet.

Notes for researchers

• If you require unambiguous structure assignment (e.g., for cheminformatics registration, LC–MS method development, or mechanistic studies), request the structure file (SMILES/SDF) and CoA.
• When registering this reagent in ELN/LIMS, retain the SKU (G1449935) and CAS for traceability until full identifiers are available.

Synthetic Utility

The Product Data do not disclose functional groups or structure; therefore, specific synthetic transformations cannot be recommended.

General strategies when structure becomes available

• Map functional handles (e.g., aryl halides, amines, acids) to diversify analogs through robust reactions (Suzuki–Miyaura, Buchwald–Hartwig, amide couplings, reductive aminations).
• Establish a rapid analoging route to explore SAR around observed activity, employing parallel synthesis and late-stage diversification if possible.
• Install tags or linkers at non-critical positions for target-ID workflows (e.g., photoaffinity, biotinylation) guided by preliminary SAR.

Analytical support

• Use LC–MS to track reaction progress and purity; verify structures by NMR (1H, 13C, HSQC/HMBC) and HRMS when advancing hits.

Note: Until the full structure is obtained from the CoA/Spec Sheet, treat GBD-9 primarily as a screening test article rather than a synthetic building block.

Target Specificity

Target information is not provided for this product.

• Known targets/epitopes: Not specified for this item; refer to CoA/Spec Sheet.
• Assay-validated selectivity: Not specified for this item; refer to CoA/Spec Sheet.

Guidance for users

• If activity is observed in a primary screen, assess specificity via orthogonal assays, concentration–response curves, and counter-screens against related targets.
• Employ cheminformatics filters (PAINS, aggregator flags) once the structure is available to contextualize apparent activity.